RS53249B - Inhibitori cxcr1/2 kao adjuvansi u transplantaciji pankreasnih ostrvaca - Google Patents

Inhibitori cxcr1/2 kao adjuvansi u transplantaciji pankreasnih ostrvaca

Info

Publication number
RS53249B
RS53249B RS20140102A RSP20140102A RS53249B RS 53249 B RS53249 B RS 53249B RS 20140102 A RS20140102 A RS 20140102A RS P20140102 A RSP20140102 A RS P20140102A RS 53249 B RS53249 B RS 53249B
Authority
RS
Serbia
Prior art keywords
transplantation
reparixin
mice
inhibitor
cxcr1
Prior art date
Application number
RS20140102A
Other languages
English (en)
Serbian (sr)
Inventor
Lorenzo Piemonti
Luisa Daffonchio
Marcello Allegretti
Original Assignee
Dompé S.p.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompé S.p.A. filed Critical Dompé S.p.A.
Publication of RS53249B publication Critical patent/RS53249B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RS20140102A 2009-10-06 2010-10-06 Inhibitori cxcr1/2 kao adjuvansi u transplantaciji pankreasnih ostrvaca RS53249B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09172364A EP2308484A1 (en) 2009-10-06 2009-10-06 Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
PCT/EP2010/064921 WO2011042466A1 (en) 2009-10-06 2010-10-06 Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets

Publications (1)

Publication Number Publication Date
RS53249B true RS53249B (sr) 2014-08-29

Family

ID=41818891

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20140102A RS53249B (sr) 2009-10-06 2010-10-06 Inhibitori cxcr1/2 kao adjuvansi u transplantaciji pankreasnih ostrvaca

Country Status (24)

Country Link
US (1) US20120202884A1 (enExample)
EP (2) EP2308484A1 (enExample)
JP (2) JP5834010B2 (enExample)
KR (2) KR101817912B1 (enExample)
CN (2) CN104906572A (enExample)
AU (1) AU2010305385B2 (enExample)
BR (1) BR112012007991B8 (enExample)
CA (1) CA2775902C (enExample)
CY (1) CY1115018T1 (enExample)
DK (1) DK2485723T3 (enExample)
EA (1) EA021298B1 (enExample)
ES (1) ES2451349T3 (enExample)
HK (1) HK1213777A1 (enExample)
HR (1) HRP20140202T1 (enExample)
IL (1) IL219037A (enExample)
ME (1) ME01719B (enExample)
MX (1) MX2012004082A (enExample)
NZ (1) NZ599172A (enExample)
PL (1) PL2485723T3 (enExample)
PT (1) PT2485723E (enExample)
RS (1) RS53249B (enExample)
SI (1) SI2485723T1 (enExample)
SM (1) SMT201400033B (enExample)
WO (1) WO2011042466A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2308485A1 (en) 2009-10-06 2011-04-13 Dompé S.p.a. Sulfonamides for the prevention of diabetes
EP2308484A1 (en) * 2009-10-06 2011-04-13 Dompé S.p.a. Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
CN103159652B (zh) * 2011-12-19 2016-06-08 天津市国际生物医药联合研究院 亚磺酰胺类化合物的制备及其应用
CN105722972A (zh) 2013-06-18 2016-06-29 纽约大学 参与金黄色葡萄球菌杀白细胞素的细胞毒性的细胞因素：新型治疗靶点
CN109890364B (zh) 2016-10-03 2023-10-17 儿童医疗中心公司 糖尿病肾病的预防和治疗

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1303249B1 (it) 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
US20020042370A1 (en) * 2000-04-14 2002-04-11 Millennium Pharmaceuticals, Inc. Method of treating graft rejection using inhibitors of CCR2 function
WO2001078708A1 (en) * 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Treating graft rejection with cxcr3 inhibitors
ITMI20010206A1 (it) 2001-02-02 2002-08-02 Dompe Spa Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz
PT1776336E (pt) * 2004-03-23 2009-12-18 Dompe Spa Derivados de ácido 2-fenilpropiónico e composições farmacêuticas que os contêm
EP1579859B1 (en) 2004-03-25 2006-12-13 DOMPE' pha.r.ma s.p.a. Use of N-(2-aryl-propionyl)-sulfonamides for the treatment of spinal cord injury
US20050261762A1 (en) * 2004-05-21 2005-11-24 Medtronic Vascular, Inc. Medical devices to prevent or inhibit restenosis
TWI400232B (zh) * 2004-09-13 2013-07-01 Ono Pharmaceutical Co 含氮雜環衍生物及以該含氮雜環衍生物為有效成分之藥劑
JP5232144B2 (ja) * 2006-06-28 2013-07-10 サノフイ Ｃｘｃｒ２阻害剤
JP2010504996A (ja) * 2006-09-26 2010-02-18 ケース ウエスタン リザーブ ユニバーシティ サイトカインシグナリング
WO2009117706A2 (en) 2008-03-20 2009-09-24 Carolus Therapeutics, Inc. Methods of treatment using anti-mif antibodies
EP2308484A1 (en) * 2009-10-06 2011-04-13 Dompé S.p.a. Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets

Also Published As

Publication number Publication date
EP2485723B1 (en) 2013-12-11
SMT201400033B (it) 2014-07-07
BR112012007991A2 (pt) 2017-07-25
EA201270513A1 (ru) 2012-11-30
MX2012004082A (es) 2012-07-25
EA021298B1 (ru) 2015-05-29
DK2485723T3 (en) 2014-03-17
US20120202884A1 (en) 2012-08-09
KR101817912B1 (ko) 2018-02-21
KR101759362B1 (ko) 2017-07-18
JP2015145404A (ja) 2015-08-13
CY1115018T1 (el) 2017-01-25
JP2013506704A (ja) 2013-02-28
SI2485723T1 (sl) 2014-06-30
EP2308484A1 (en) 2011-04-13
EP2485723A1 (en) 2012-08-15
ME01719B (me) 2014-09-20
CN102665703A (zh) 2012-09-12
CN102665703B (zh) 2016-04-20
AU2010305385B2 (en) 2016-04-21
JP6097328B2 (ja) 2017-03-15
HRP20140202T1 (en) 2014-05-23
HK1213777A1 (zh) 2016-07-15
BR112012007991B8 (pt) 2021-05-25
AU2010305385A1 (en) 2012-04-26
NZ599172A (en) 2014-03-28
BR112012007991B1 (pt) 2020-12-15
PT2485723E (pt) 2014-03-13
CN104906572A (zh) 2015-09-16
CA2775902A1 (en) 2011-04-14
IL219037A (en) 2015-01-29
IL219037A0 (en) 2012-06-28
JP5834010B2 (ja) 2015-12-16
CA2775902C (en) 2016-11-29
ES2451349T3 (es) 2014-03-26
KR20120083440A (ko) 2012-07-25
HK1175993A1 (zh) 2013-07-19
KR20170068625A (ko) 2017-06-19
PL2485723T3 (pl) 2014-07-31
WO2011042466A1 (en) 2011-04-14

Similar Documents

Publication Publication Date Title
KR100206054B1 (ko) 당뇨병 치료용 조성물
EP1429845B1 (en) Treatment or prophylaxis of insulin-producing cell graft rejection
NO338800B1 (no) Medikamenter med reduserende virkning på lymfocytter i det perifere kretsløp
RS53249B (sr) Inhibitori cxcr1/2 kao adjuvansi u transplantaciji pankreasnih ostrvaca
US20230414675A1 (en) Use of anti-aging glycopeptides to enhance pancreatic cell health, survival and improve transplant outcome
AU2002320828A1 (en) Treatment or prophylaxis of insulin-producing cell graft rejection
JP5745526B2 (ja) 糖尿病の予防のためのスルホンアミド
EP3878443A1 (en) Composition for preventing and treating transplant rejection or transplant rejection diseases, comprising novel compound and calcineurin inhibitor
US10016376B2 (en) Composition for alleviating nephrotoxicity caused by immunosuppressive drug, comprising metformin, and composition for preventing or treating immune disease, comprising the same
HK1175993B (en) Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
Piemonti et al. Islet cell or pancreas transplantation
Teahan et al. Immunosuppressive Agents in Pancreatic Transplantation
Faradji et al. METABOLIC EFFECTS OF EXENATIDE IN POST ISLET TRANSPLANT RECIPIENTS.
Froud et al. THE USE OF EXENATIDE TO IMPROVE ISLET ENGRAFTMENT, FUNCTION AND LONG TERM SURVIVAL.
Rilo et al. 68 ISLET AUTO TRANSPLANTS AT THE UNIVERSITY OF CINCINNATI: A 5 YEAR EXPERIENCE.